The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

The agency authorized Novavax to start a Phase 3 trial of its combination shot after the company “satisfactorily” addressed ...

Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

(RTTNews) - Novavax, Inc. (NVAX) Monday said the Food and Drug Administration or FDA has removed the clinical hold on its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine ...

Novavax (NVAX) shares surge 12% as FDA lifts clinical hold on COVID-19-Influenza Combination vaccine candidates.

Novavax said that it provided additional information to the FDA, leading to the conclusion that the event was not related to the vaccine. The company said it would be working to start a Phase 3 trial ...

The FDA has cleared the company to begin enrolling the planned Phase 3 trial following the determination that Novavax satisfactorily addressed all clinical hold issues. Novavax will be working with ...

Investing.com -- The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s ...

The standalone COVID-19 vaccine—the company’s only product currently on the U.S. market, in competition with big hitters Pfizer/BioNTech and Moderna—is not impacted by the FDA’s hold, Novavax said. In ...